Jaguar Health Inc (JAGX) Q3 2026 Earnings Call Highlights: Debt Cut by $10 Million
Jaguar Health (JAGX) reported Q3 2026 net loss decreased by $3.8M to $5.8M, debt reduced by $10M. CEO Conti cited clinical data showing crofelemer's efficacy in rare intestinal diseases. CFO Lizak noted revenue fell to $500K due to licensing agreement. Management highlighted blockbuster potential in global intestinal failure market.
